Recursion Pharmaceuticals Inc (RXRX)
5.70
-0.05
(-0.87%)
USD |
NASDAQ |
Nov 22, 16:00
5.75
+0.05
(+0.88%)
After-Hours: 20:00
Recursion Pharmaceuticals Cash from Investing (Quarterly): -4.562M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -4.562M |
June 30, 2024 | -4.182M |
March 31, 2024 | -6.653M |
December 31, 2023 | -2.488M |
September 30, 2023 | -0.347M |
June 30, 2023 | -2.053M |
March 31, 2023 | -5.34M |
December 31, 2022 | -7.979M |
September 30, 2022 | 52.98M |
June 30, 2022 | 4.94M |
Date | Value |
---|---|
March 31, 2022 | 143.30M |
December 31, 2021 | -52.24M |
September 30, 2021 | -193.87M |
June 30, 2021 | -6.212M |
March 31, 2021 | -19.42M |
December 31, 2020 | -4.591M |
September 30, 2020 | -3.426M |
June 30, 2020 | -0.039M |
March 31, 2020 | -0.684M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-193.87M
Minimum
Sep 2021
143.30M
Maximum
Mar 2022
-5.94M
Average
-4.182M
Median
Jun 2024
Cash from Investing (Quarterly) Benchmarks
Revance Therapeutics Inc | 23.29M |
NovaBay Pharmaceuticals Inc | -0.002M |
Palatin Technologies Inc | 0.00 |
iBio Inc | 0.713M |
Theriva Biologics Inc | 0.00 |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -59.22M |
Cash from Financing (Quarterly) | 16.46M |
Free Cash Flow | -335.64M |
Free Cash Flow Per Share (Quarterly) | -0.2257 |
Free Cash Flow to Equity (Quarterly) | -61.49M |
Free Cash Flow to Firm (Quarterly) | -63.79M |
Free Cash Flow Yield | -23.96% |